AstraZeneca : AstraZeneca offers us some Easter eggs
>Two pieces of good news which support our investment case - Whilst we have certainly had better Easter weekends (blame confinement), the AstraZeneca Easter weekend was a very good one. The company reported two pieces of good news: 1/ the lifting of the blind 2 years ahead of schedule of a phase III trial of Tagrisso because of its overwhelming efficacy and 2/ the approval in the US of a new product, Koselugo (selumetinib), in tumours caused by a rare disease, neurof...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.